1729P Influence of recent administration and type of oncological treatment (T) in survival of oncological patients (p) with COVID-19: Experience of Vall d’Hebron University Hospital

Background: SARS-CoV-2 outbreak has impacted on the management of oncological p, leading to treatment delays in a considerable number of cases The aim of this study was to evaluate if oncological T affected negatively COVID-19 outcome Methods: We retrospectively analyzed clinical data from p with solid tumors under active systemic T (received in the last 6 months) that were diagnosed with SARS-CoV-2 infection (defined as positive PCR) between March and 11th May 2020 in our center Study endpoint was death due to COVID-19 We divided the patients in two groups;those who had received treatment in the last 4 weeks and those who had not Descriptive and univariate analysis were performed to detect the effect of T type and other variables on COVID-19 related mortality Results: A total of 70 p were included with a median follow-up of 28 days (10-47) and active oncological T had been administered in the past 4 weeks to 44 p Median age was 66 (IQR 56-74), 23 p (52 27%) were female and 41 (93 2%) had a baseline ECOG≤1 The most frequent primary site was lung tumor (12 p [27 3%]), followed by breast (11 p [25%]) and gastrointestinal (5 p [11 4%]) Thirty-one p (70 5%) had metastatic disease and 13 (29 5%) were included in clinical trials Twenty-four p (54 5%) received chemotherapy (CT), 14 (31 8%) targeted therapies, 9 (20 4%) immunotherapy (IT), 5 (11 4%) radiotherapy and 6 (13 6%) hormonotherapy A total of 13 p (29 5%) received different combinations of oncological T Death due to COVID-19 occurred in 5/22 (22 7%) p receiving CT and 6/21 (28 5%) p in the non-CT (p>0 05) Only 1/9 (11 1%) p treated with IT died compared to 11/35 (31 4%) p in the rest of the cohort (p>0 05) Age>71, comorbidities such as chronic obstructive pulmonary disease and ECOG status>2 were associated to a higher mortality The distribution of these variables between the anticancer T groups was not different Conclusions: Our results suggest that CT and other anticancer T might not worsen COVID-19 related mortality;nevertheless, the number of patients was small and decision making has to be individualized Our findings may warrant further investigation in larger studies Legal entity responsible for the study: The authors Funding: Has not received any funding Disclosure: E Felip: Advisory/Consultancy, Speaker Bureau/Expert testimony: AbbVie;AstraZeneca;Blueprint medicines;Boehringer Ingelheim;Bristol-Myers Squibb;Celgene;Eli Lilly;Guardant Health;Janssen;Medscape;Merck KGaA;Novartis;Pfizer;Roche;Takeda;Touchtime;Research grant/Funding (self), Research grant/Funding (institution): Fundacion Merck Salud;Oncology Innovation EMD Serono J Carles: Advisory/Consultancy, Speaker Bureau/Expert testimony: Johnson & Johnson;Bayer;Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self): Astellas Pharma;Advisory/Consultancy: Pfizer;Sanofi;MSD Oncology;Advisory/Consultancy, Research grant/Funding (self): Roche;Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: AstraZeneca;Speaker Bureau/Expert testimony: Asofarma;Research grant/Funding (self), Travel/Accommodation/Expenses: BMS;ravel/Accommodation/Expenses: Ipsen;Roche;Research grant/Funding (self): AB Science;Aragon Pharmaceuticals;Pharmaceuticals;INC;Blueprint Medicines Corporation;N Immunotherapeutics INC;Boehringer Ingelheim Espana, S A ;Clovis Oncology;Cougar Biotechnology INC;Deciphera Pharmaceuticals LLC;Exelixis INC;F Hoffmann-La Roche LTD;Genentech INC;Glaxosmithkline;Incyte Corporation;Janssen-Cilag International NV;Karyopharm Therapeutics INC;Laboratoires Leurquin Mediolanum SAS J Tabernero: Honoraria (self): Array Biopharma;AstraZeneca;Bayer;BeiGene;Boehringer Ingelheim;Chugai;Genentech;Genmab A/S;Halozyme;Imugene Limited;Inflection Biosciences Limited;Ipsen;Kura Oncology;Lilly;MSD;Merck Serono;Menarini;Merrimack;Merus;Molecular Partners;Novartis;Peptomyc;Pfizer;Pharmacyclics;ProteoDesign SL;Rafael Pharmaceuticals;F Hoffmann-La Roche Ltd;): Sanofi;eaGen;Seattle Genetics, Servier, Symphogen, Taiho, VCN Biosciences, Biocartis, Foundation Medicine, HalioDX SAS and Roche Diagnostics All other authors have declared no conflicts of interest